DAB₃₈₉IL2 (ONTAK^®) fusion protein therapy of chronic lymphocytic leukaemia

Bibliography

• ZENT CS, KYASA MJ, EVANS R, SCHICHMAN SA: Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer (2001) 92:1325–1330.
   PubMed Web of Science ®Google Scholar
• KLEIN U, TU Y, STOLOVITZKY GA et al.: Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J. Exp. Med. (2001) 194:1625–1638.
   PubMed Web of Science ®Google Scholar
• STILGENBAUER S, BULLINGER L, LICHTER P, DOHNER H: Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia (2002) 16:993–1007.
   PubMed Web of Science ®Google Scholar
• TSUKADA N, BURGER JA, ZVAIFLER NJ, KIPPS TJ: Distinctive features of `nurselike' cells that differentiate in the context of chronic lymphocytic leukemia. Blood (2002) 99:1030–1037.
   PubMed Web of Science ®Google Scholar
• ROZMAN C, MONTSERRAT E: Chronic lymphocytic leukemia. N Eng. I Med. (1995) 333:1052–1057.
   PubMed Web of Science ®Google Scholar
• DIRAIMONDO F, ALBITAR M, HUH Y et al.: The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease. Cancer (2002) 94: 1721-1730.
   Google Scholar
• DHODAPKAR M, TEFFERI A, SU J, PHYLIKY RL: Prognostic features and survival in young adults with early/ intermediate chronic lymphocytic leukemia(B-CLL): a single institution study. Leukemia (1993) 7:1232–1235.
   PubMed Web of Science ®Google Scholar
• HAN T, BARCOS M, EMRICH L et al: Bone marrow infiltration patterns and their prognostic significance in chronic lymphocytic leukemia: correlations with clinical, immunologic, phenotypic, and cytogenetic data. Clin. Oncol (1984) 2:562–570.
   Web of Science ®Google Scholar
• STRATOWA C, LOFFLER G, LICHTER P et al: cDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking. Int. J. Cancer (2001) 91:474–480.
   PubMed Web of Science ®Google Scholar
• FADERL S, KEATING MJ, DO KA et al: Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia. Leukemia (2002) 16:1045–1052.
   PubMed Web of Science ®Google Scholar
• OSCIER DG, GARDINER AC, MOULD SJ et al.: Multivariate analysis of prognostic factors in CLL: clinical stage, IgVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood (2002) 100:1177–1184.
   PubMed Web of Science ®Google Scholar
• CONSOLI U, SANTONOCITO A, STAGNO F et al.: Multidrug resistance mechanisms in chronic lymphocytic leukaemia. Br. Haematol (2002) 116:774–780.
   PubMed Web of Science ®Google Scholar
• DONEY KC, CHAUNCEY T, APPELBAUM FR: Allogeneic related donorhematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. Bone Marrow Transplant. (2002) 29:817–823.
   PubMed Web of Science ®Google Scholar
• KHOURI IF, KEATING MJ, SALIBA PM, CHAMPLIN RE. Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy (2002) 4:217–221.
   PubMed Web of Science ®Google Scholar
• DREGER P, MONTSERRAT E: Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia (2002) 16:985–992.
   PubMed Web of Science ®Google Scholar
• CHESON BD, BENNETT JM, GREVER M et al.: National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood (1996) 87:4990–4997.
   PubMed Web of Science ®Google Scholar
• RAI K, PETERSON BL, APPELBAUM FR et al.: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Eng. I Med. (2000) 343:1750–1757.
   PubMed Web of Science ®Google Scholar
• SCHMITT B, WENDTNER CM, BERGMANN M et al: Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia. Clin. Lymphoma (2002) 3:26–35.
   Google Scholar
• LUNDIN J, KIMBY E, BJORKHOLM M et al.: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocyticleukemia (B-CLL). Blood (2002) 100:768–773.
   PubMed Web of Science ®Google Scholar
• KEATING MJ, O& BRIEN S, ALBITAR M: Emerging information on the use of rituximab in chronic lymphocytic leukemia. Semin. Oncol (2002) 29\(Suppl. 2):70–74.
   Google Scholar
• NABHAN C, ROSEN ST: Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia. Semin. Oncol. (2002) 29\(Suppl. 2):75–80.
   Google Scholar
• KEATING MJ, FLINN I, JAIN Vet al.: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood (2002) 99:3554–3561.
   Google Scholar
• KENNEDY B, RAWSTRON A, CARTER C et al: Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood (2002) 99:2245–2247.
   PubMed Web of Science ®Google Scholar
• O'BRIEN SM, KANTARJIAN H, THOMAS DA et al.: Rituximab dose-escalation trial in chronic lymphocytic leukemia. Clin. Omni (2001) 19:2165–2170.
   Google Scholar
• BYRD JC, MURPHY T, HOWARD RS et al.: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.Clin. Oncol (2001)19:2153–2164.
   Web of Science ®Google Scholar
• PERKINS JG, FLYNN JM, HOWARD RS, BYRD JC: Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer (2002) 94:2033–2039.
   PubMed Web of Science ®Google Scholar
• FRANKEL AE, POWELL BL, VALLERA DA, NEVILLE DM: Chimeric fusion proteins- diphtheria toxin-based. Curc Opin. Invest. Drugs (2001) 2:1294–1301.
   PubMedGoogle Scholar
• ELLERY JM, NICHOLLS PJ: Alternate signaling pathways from the interleukin-2 receptor. Cytokine Growth Factor Rev (2002) 3:27–40.
   Web of Science ®Google Scholar
• WEISS LM, MICHIE SA, MEDEIROS LJ, STRICKLER JG, GARCIA CEWARNKE RA: Expression of Tac antigen by non-Hodgkin's lymphomas. Am. I Clin. Pathol (1987) 88:483–485.
   PubMed Web of Science ®Google Scholar
• ROSOLEN A, NAKANISHI M, POPLACK DG et al.: Expression of interleukin-2 receptor beta subunit in hematopoietic malignancies. Blood (1989) 73: 1968-1972.
   Google Scholar
• DAMLE RN, GHIOTTO F, VALETTO A et al.: B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood (2002) 99:4087–4093.
   PubMed Web of Science ®Google Scholar
• TSILIVAKOS V, TSAPIS A, KOKOLYRIS S, ILIAKIS P, PERRAKI M, GEORGOULIAS V: Characterization of interleukin 2 receptors on B-cell chronic lymphocytic leukemia cells. Leukemia (1994) 8:1571–1578.
   PubMed Web of Science ®Google Scholar
• NAKASE K, KITA K, NASU K et al: Differential expression of interleukin-2 receptors (alpha and beta chain) in mature lymphoid neoplasms. Am. j Hematol (1994) 46:179–183.
   PubMed Web of Science ®Google Scholar
• SHEIBANI K, WINBERG CD, VAN DE VELDE S, BLAYNEY DW,RAPPAPORT H: Distribution of lymphocytes with interleukin-2 receptors (TAC antigens) in reactive lymphoproliferative processes, Hodgkin's disease, and non-Hodgkin's lymphomas. An immunohistologic study of 300 cases. Am. J. Pathol (1987) 127:27–37.
   PubMed Web of Science ®Google Scholar
• CHOE S, BENNETT MJ, FUJII G et al: The crystal structure of diphtheria toxin. Nature (1992) 357:216–222.
   PubMed Web of Science ®Google Scholar
• BROOKE JS, CHA JH: Molecular characterization of key diphtheria toxin: receptor interactions. Biochem. Biophys. Res. Commun. (2000) 275:374–381.
   PubMed Web of Science ®Google Scholar
• SIMPSON JC, SMITH DC, ROBERTS LM, LORD JM: Expression of mutant dynamin protects cells against diphtheria toxin but not against ricin. Exp. Cell Res. (1998) 239:293–300.
   PubMed Web of Science ®Google Scholar
• FALNES PO, SAND VIG K: Penetration of protein toxins into cells. Curt: Opin.Biol. (2000) 12:407–413.
   PubMed Web of Science ®Google Scholar
• BELL CE, EISENBERG D: Crystal structure of diphtheria toxin bound to nicotinamide adenine dinucleotide. Biochemistry (1996) 35:1137–1149.
   PubMed Web of Science ®Google Scholar
• VAN DER SPEK JC, MURPHY JR: Fusion protein toxins based on diphtheria toxin: selective targeting of growth factor receptors of eukaryotic cells. Methods Enzymol (2000) 327:239–249.
   PubMed Web of Science ®Google Scholar
• WILLIAMS DP, SNIDER CE, STROM TB, MURPHY JR: Structure/function analysis of interleukin-2-toxin(DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J. Biol. Chem. (1990) 265:11885–11889.
   Google Scholar
• RE GG, WATERS C, POISSON L, WILLINGHAM MC, SUGAMURA K, FRANKEL AE: Intedeukin 2 (IL-2) receptor expression and sensitivity to diphtheria fusion toxin DAB389IL-2 in cultured hematopoietic cells. Cancer Res. (1996) 56:2590–2595.
   PubMed Web of Science ®Google Scholar
• BACHA PA, FORTE SE, MCCARTHY DM, ESTIS L, YAMADA G, NICHOLS JC: Impact of interleukin-2-receptor-targeted cytotwdns on a unique model of murine interleukin-2-receptor-expressing malignancy. Int. Cancer (1991) 49:96–101.
   PubMed Web of Science ®Google Scholar
• LEMAISTRE CE SALEH MN, KUZEL TM et al.: Phase I trial of a ligand-fusion protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood (1998) 91:399–405.
   Google Scholar
• OLSEN E, DUVIC M, FRANKEL A et al: Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. j Clin. Omni (2001) 19:376–388.
   PubMed Web of Science ®Google Scholar
• FOSS FM, BACHA P, OSANN KE, DEMIERRE ME BELL T, KUZEL T: Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin. Lymphoma (2001) 1:298–302.
   PubMedGoogle Scholar
• RAILAN D, FIVENSON DP, WITTENBERG G: Capillary leak syndrome in a patient treated with interleukin 2 fusion toxin for cutaneous T-cell lymphoma. Am. Acad. Dermatol (2000) 43:323–324.
   PubMed Web of Science ®Google Scholar
• ACOSTA M, TEITELBAUM A: Capillary leak syndrome in a patient treated with interleukin 2 fusion toxin for cutaneous T-cell lymphoma. Am. Acad. Dermatol (2001) 44:312–313.
   PubMed Web of Science ®Google Scholar
• Ontak Package Insert (1999). San Diego, CA: Ligand Pharmaceuticals, Incorporated; February 5, 1999.
   Google Scholar
• TALPUR R, APISARNTHANARAX N, WARD S, DUVIC M: Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). Leak. Lymphoma (2002) 43:121–126.
   PubMed Web of Science ®Google Scholar
• GORGUN G, FOSS F:Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood (2002) 100:1399–1403.
   PubMed Web of Science ®Google Scholar
• NAKASE K, KITA K, SHIRAKAWA S, TANAKA I, TSUDO M: Induction of cell surface interleukin 2 receptor alpha chain expression on non-T lymphoid leukemia cells. Leak. Res. (1994) 18:855–859.
   PubMed Web of Science ®Google Scholar
• DECKER T, HIPP S, KREITMAN RJ, PASTAN I, PESCHEL C, LICHT T: Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. Blood(2002) 99:1320–1326.
   PubMed Web of Science ®Google Scholar
• DIGEL W, SCHMID M, HEIL G, CONRAD P, GILLIS S, PORZSOLT F: Human interleukin-7 induces proliferation of neoplastic cells from chronic lymphocytic leukemia and acute leukemias. Blood (1991) 78:753–579.
   PubMed Web of Science ®Google Scholar
• TRENTIN L, ZAMBELLO R, AGOSTINI C et al.: Expression and regulation of tumor necrosis factor, interleukin-2, and hematopoietic growth factor receptors in B-cell chronic lymphocytic leukemia. Blood (1994) 84:4249–4256.
   PubMed Web of Science ®Google Scholar
• BAMBOROUGH P, HEDGECOCK CJ, RICHARDS WG: The interleukin-2 and interleukin-4 receptors studied by molecular modelling. Structure (1994) 2:839–851.
   PubMed Web of Science ®Google Scholar
• THORNTON PD, HAMBLIN M, TRELEAVEN JG, MATUTES E, LAKHANI AK, CATOVSKY D: High dose methylprednisolone in refractory chronic lymphocytic leukemia. Leak. Lymphoma (1999) 34:167–170.
   PubMed Web of Science ®Google Scholar